

For immediate release

11 August 2005

PROTEOME SCIENCES TMT REAGENTS LICENSE UPDATE

The Directors of Proteome Sciences plc announce that the process of concluding a licence agreement for the company's Tandem Mass Tags® (TMT®) is continuing satisfactorily, and that a further announcement will be made when the deal is formally concluded.

Enquiries:

Proteome Sciences plc

Christopher Pearce, Chief Executive
James Malthouse, Finance Director

01932 865065

Dresdner Kleinwort Wasserstein

Michael Covington

020 7623 8000

IKON Associates

Adrian Shaw

01483 535102

07979 900733

Notes to Editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has to date developed sensitive blood assays for stroke, vCJD, BSE, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoSHOP (Proteome Sciences High Output Proteomics), a toolbox that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification of potential biomarkers and drug targets. These include specialisation in membrane proteins and protein phosphorylation.

The Company has also developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass

spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer, PST, qPST and TMT.

The process of commercialisation is being actively pursued across the portfolio of the Company's programmes and technologies and to date licensing deals have been signed for the commercialisation of tests for Stroke and TSEs.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and in Frankfurt. It employs 40 full time scientists in addition to its corporate and business development staff. The Company is listed on the Alternative Investment Market.

ENDS